borderline significantp = 0.05
In chronic patients (7 trials, N = 194), the MD was 2.20 points (95% CI -0.01 to 4.40), an effect that was borderline significant ( p = 0.05), with no heterogeneity (I2 = 0%).
In chronic patients (7 trials, N = 194), the MD was 2.20 points (95% CI -0.01 to 4.40), an effect that was borderline significant ( p = 0.05), with no heterogeneity (I2 = 0%).
While subgroup analysis revealed a marginally non-significant effect in the subacute phase (MD = 0.88; p = 0.05) and a non-significant effect in the chronic phase, the test for subgroup differences was not significant ( p = 0.91), suggesting comparable benefits regardless of recovery stage.